BASF's Evonik Bid Needs a Rationale, Not Just a Bigger Cheque
Published on 11/18/2026 at 12:01 | Editorial boerse-global.deBASF's courtship of Evonik has reached a stage where the price tag is no longer the whole story. According to Reuters, citing sources close to Evonik, a sweeter offer on its own would not be enough to win the day — a signal that the industrial logic behind any deal now matters more to BASF shareholders than the next round of bidding.
The numbers under discussion are already moving. Handelsblatt, citing financial circles, reports that a possible new offer could land between 26 and 28 euros per Evonik share, against the 24 euros BASF has put on the table so far. No formal new bid has yet been submitted. That gap describes a negotiating range, not an agreed purchase price or a confirmed breakthrough — a distinction investors would do well to keep in mind before treating a higher figure as a share-price catalyst in its own right.
Two Questions, Not One
The hurdle set by the Reuters account is straightforward: more money might get talks moving, but it would not substitute for the justification Evonik's camp is demanding. For BASF's owners, that splits the issue in two. Could an improved offer bring the other side around? And would the capital committed be persuasive for BASF itself? A yes to the first does not automatically answer the second.
Bloomberg reports that BASF is preparing an improved bid and weighing extra commitments on jobs and investment in Germany. Such pledges could form part of a broader proposal, though their value would hinge on whether they sit alongside a coherent economic case — not stand in for one. Given the reservations reported, they would not be sufficient on their own.
Should investors sell immediately? Or is it worth buying BASF?
What a Credible Package Would Look Like
The upbeat scenario is a proposal that ties price, industrial rationale and possible commitments together in a way that adds up. A higher offer would then not read as an isolated burden, and shareholders could judge it against the value BASF expects to create and the obligations it would take on. That would amount to more than another round of haggling — it could soften the standoff now being described. The verdict, though, can only come once a concrete bid is on the table.
BASF has other outlets for its capital in the meantime. The company reported further share buybacks on Monday, and on 11 November it officially commissioned its new MDI production plant at the Geismar integrated site, an investment of 1 billion US dollars. Neither move proves anything about an Evonik deal, but together they set the benchmark: any acquisition would have to justify itself alongside spending on BASF's own assets and its buyback programme.
The Cost of Sweeteners
The downside scenario is a pricier offer that still fails to convince on industrial grounds. BASF would then be committing more capital without clearing the decisive objection — a bigger number, under those conditions, would be no reliable sign of progress. Add potential commitments on jobs and investment, whose weight can only be judged from their specific terms, and the picture gets more complicated. Reuters reports that BASF discussed possible pledges on sites, employment and training with stakeholders yesterday, with the conditions of a new offer still open.
That leaves shareholders with a genuine trade-off. What might smooth the path to approval would also have to square with the deal's economic logic. The more extensive the overall package, the more important a convincing account of its benefit to BASF becomes. Negotiating progress and value creation, in other words, need to be assessed separately.
Beyond the Chemicals Deal
Elsewhere, BASF is pushing the global rollout of its Nemasphere soybean technology, with varieties carrying the trait due to be available in the US and Brazil from 2028, the company said on Monday. It also signed an agreement on 12 November to sell its mining business to SNF, with closing expected in 2027 subject to regulatory approvals and customary conditions. And the Geismar ramp-up lifts the site's annual MDI capacity to roughly 600,000 tonnes.
BASF at a turning point? This analysis reveals what investors need to know now.
Analysts are not uniformly enthusiastic. Jefferies downgraded BASF from "Hold" to "Underperform" on 11 November, keeping its price target at 44 euros. The stock was down 0.6% today.
The next real catalyst, then, is the possible submission of an improved formal offer — and the terms and reasoning behind it will matter more than the headline price. For investors the test is simple: progress would have to strengthen both the odds of approval and the economic plausibility for BASF. Only that combination would turn a fresh bid into a genuinely better prospect.
Ad
BASF Stock: New Analysis - 18 November
Fresh BASF information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
